Gates Foundation Strategic Investment Fund Logo
Share this page:

PR Newswire: The Global Health Investment Fund and Medicines Development for Global Health Announce the Sale of Priority Review Voucher

May 07, 2019

NEW YORK and MELBOURNE, AustraliaMay 7, 2019 /PRNewswire/ — The Global Health Investment Fund (GHIF) and Medicines Development for Global Health (MDGH) today announced the sale of  MDGH’s Priority Review Voucher (PRV). The PRV was awarded to MDGH in June 2018 by the U.S. Food & Drug Administration (FDA) following the FDA’s approval of moxidectin, an oral treatment for river blindness (onchocerciasis), a debilitating disease affecting 20 million people, primarily in low-income countries. GHIF provided $13 million since 2015 to support MDGH’s efforts to complete clinical studies, manufacture moxidectin and conduct the FDA registration process.

Read the full text here.